25 XP   0   0   10

Ocular Therapeutix Inc
Buy, Hold or Sell?

Let's analyse Ocular Therapeutix Inc together

PenkeI guess you are interested in Ocular Therapeutix Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ocular Therapeutix Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ocular Therapeutix Inc

I send you an email if I find something interesting about Ocular Therapeutix Inc.

Quick analysis of Ocular Therapeutix Inc (30 sec.)










What can you expect buying and holding a share of Ocular Therapeutix Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
15.0%

What is your share worth?

Current worth
$0.61
Expected worth in 1 year
$0.99
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$0.38
Return On Investment
8.9%

For what price can you sell your share?

Current Price per Share
$4.20
Expected price per share
$3.46 - $11.31
How sure are you?
50%

1. Valuation of Ocular Therapeutix Inc (5 min.)




Live pricePrice per Share (EOD)

$4.20

Intrinsic Value Per Share

$-6.91 - $-4.72

Total Value Per Share

$-6.30 - $-4.10

2. Growth of Ocular Therapeutix Inc (5 min.)




Is Ocular Therapeutix Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$91.1m$56.8m-$28.8m-103.3%

How much money is Ocular Therapeutix Inc making?

Current yearPrevious yearGrowGrow %
Making money-$21.7m-$15.8m-$5.8m-26.9%
Net Profit Margin-152.3%-126.5%--

How much money comes from the company's main activities?

3. Financial Health of Ocular Therapeutix Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#384 / 1010

Most Revenue
#255 / 1010

Most Profit
#712 / 1010

Most Efficient
#604 / 1010

What can you expect buying and holding a share of Ocular Therapeutix Inc? (5 min.)

Welcome investor! Ocular Therapeutix Inc's management wants to use your money to grow the business. In return you get a share of Ocular Therapeutix Inc.

What can you expect buying and holding a share of Ocular Therapeutix Inc?

First you should know what it really means to hold a share of Ocular Therapeutix Inc. And how you can make/lose money.

Speculation

The Price per Share of Ocular Therapeutix Inc is $4.2. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ocular Therapeutix Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ocular Therapeutix Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.61. Based on the TTM, the Book Value Change Per Share is $0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ocular Therapeutix Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.20-4.7%-0.14-3.2%-0.12-2.8%-0.13-3.2%-0.11-2.6%
Usd Book Value Change Per Share0.5613.3%0.092.2%-0.09-2.1%0.020.4%0.030.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.1%
Usd Total Gains Per Share0.5613.3%0.092.2%-0.09-2.1%0.020.5%0.030.7%
Usd Price Per Share4.46-4.51-3.98-6.92-8.66-
Price to Earnings Ratio-5.67--61.88--8.93--7.70--21.29-
Price-to-Total Gains Ratio7.96--10.10--50.60-27.01--153.63-
Price to Book Ratio7.27-98.95-10.86-21.65-24.05-
Price-to-Total Gains Ratio7.96--10.10--50.60-27.01--153.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.2
Number of shares238
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.090.02
Usd Total Gains Per Share0.090.02
Gains per Quarter (238 shares)22.324.57
Gains per Year (238 shares)89.2818.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1089791188
2017916813526
3026825725344
4035734627162
5044643538880
60536524310698
706256134124116
807147025142134
908037915159152
1008938806177170

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%2.018.00.010.0%2.038.00.05.0%2.042.01.04.4%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%8.012.00.040.0%13.027.00.032.5%14.028.03.031.1%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%6.00.034.015.0%6.00.039.013.3%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%8.012.00.040.0%14.026.00.035.0%15.027.03.033.3%

Fundamentals of Ocular Therapeutix Inc

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 16:35:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ocular Therapeutix Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ocular Therapeutix Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -197.4% means that $-1.97 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ocular Therapeutix Inc:

  • The MRQ is -197.4%. The company is making a huge loss. -2
  • The TTM is -152.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-197.4%TTM-152.3%-45.1%
TTM-152.3%YOY-126.5%-25.8%
TTM-152.3%5Y-817.6%+665.3%
5Y-817.6%10Y-2,502.4%+1,684.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-197.4%-207.2%+9.8%
TTM-152.3%-216.8%+64.5%
YOY-126.5%-282.3%+155.8%
5Y-817.6%-436.8%-380.8%
10Y-2,502.4%-597.3%-1,905.1%
1.1.2. Return on Assets

Shows how efficient Ocular Therapeutix Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • -11.6% Return on Assets means that Ocular Therapeutix Inc generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ocular Therapeutix Inc:

  • The MRQ is -11.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.6%TTM-14.3%+2.7%
TTM-14.3%YOY-9.7%-4.6%
TTM-14.3%5Y-15.3%+1.1%
5Y-15.3%10Y-16.5%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.6%-13.3%+1.7%
TTM-14.3%-12.8%-1.5%
YOY-9.7%-11.6%+1.9%
5Y-15.3%-13.8%-1.5%
10Y-16.5%-15.6%-0.9%
1.1.3. Return on Equity

Shows how efficient Ocular Therapeutix Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • -32.1% Return on Equity means Ocular Therapeutix Inc generated $-0.32 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ocular Therapeutix Inc:

  • The MRQ is -32.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -270.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.1%TTM-270.9%+238.8%
TTM-270.9%YOY-31.8%-239.1%
TTM-270.9%5Y-127.3%-143.5%
5Y-127.3%10Y-76.2%-51.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.1%-16.9%-15.2%
TTM-270.9%-16.1%-254.8%
YOY-31.8%-14.9%-16.9%
5Y-127.3%-19.3%-108.0%
10Y-76.2%-20.1%-56.1%

1.2. Operating Efficiency of Ocular Therapeutix Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ocular Therapeutix Inc is operating .

  • Measures how much profit Ocular Therapeutix Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • An Operating Margin of -135.4% means the company generated $-1.35  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ocular Therapeutix Inc:

  • The MRQ is -135.4%. The company is operating very inefficient. -2
  • The TTM is -142.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-135.4%TTM-142.3%+6.8%
TTM-142.3%YOY-153.8%+11.5%
TTM-142.3%5Y-753.5%+611.2%
5Y-753.5%10Y-2,421.3%+1,667.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-135.4%-298.0%+162.6%
TTM-142.3%-238.5%+96.2%
YOY-153.8%-288.4%+134.6%
5Y-753.5%-486.2%-267.3%
10Y-2,421.3%-628.4%-1,792.9%
1.2.2. Operating Ratio

Measures how efficient Ocular Therapeutix Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.35 means that the operating costs are $2.35 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 2.354. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.422. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.354TTM2.422-0.068
TTM2.422YOY2.538-0.116
TTM2.4225Y8.604-6.182
5Y8.60410Y25.057-16.453
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3543.235-0.881
TTM2.4223.310-0.888
YOY2.5383.838-1.300
5Y8.6045.679+2.925
10Y25.0577.823+17.234

1.3. Liquidity of Ocular Therapeutix Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.66 means the company has $6.66 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 6.655. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.351. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.655TTM4.351+2.304
TTM4.351YOY5.633-1.283
TTM4.3515Y6.248-1.898
5Y6.24810Y7.934-1.686
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.6553.863+2.792
TTM4.3514.169+0.182
YOY5.6335.337+0.296
5Y6.2486.122+0.126
10Y7.9346.434+1.500
1.3.2. Quick Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Quick Ratio of 6.37 means the company can pay off $6.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 6.366. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.116. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.366TTM4.116+2.250
TTM4.116YOY5.430-1.314
TTM4.1165Y6.012-1.896
5Y6.01210Y9.283-3.271
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3663.504+2.862
TTM4.1163.991+0.125
YOY5.4305.371+0.059
5Y6.0126.088-0.076
10Y9.2836.395+2.888

1.4. Solvency of Ocular Therapeutix Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ocular Therapeutix Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ocular Therapeutix Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.64 means that Ocular Therapeutix Inc assets are financed with 63.8% credit (debt) and the remaining percentage (100% - 63.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 0.638. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.872. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.638TTM0.872-0.234
TTM0.872YOY0.666+0.206
TTM0.8725Y0.803+0.070
5Y0.80310Y0.642+0.161
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6380.339+0.299
TTM0.8720.337+0.535
YOY0.6660.271+0.395
5Y0.8030.368+0.435
10Y0.6420.388+0.254
1.4.2. Debt to Equity Ratio

Measures if Ocular Therapeutix Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 176.6% means that company has $1.77 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ocular Therapeutix Inc:

  • The MRQ is 1.766. The company is just able to pay all its debts with equity.
  • The TTM is 18.096. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ1.766TTM18.096-16.330
TTM18.096YOY2.158+15.938
TTM18.0965Y6.441+11.656
5Y6.44110Y3.443+2.997
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7660.392+1.374
TTM18.0960.403+17.693
YOY2.1580.335+1.823
5Y6.4410.427+6.014
10Y3.4430.461+2.982

2. Market Valuation of Ocular Therapeutix Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ocular Therapeutix Inc generates.

  • Above 15 is considered overpriced but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
  • A PE ratio of -5.67 means the investor is paying $-5.67 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ocular Therapeutix Inc:

  • The EOD is -5.341. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.671. Based on the earnings, the company is expensive. -2
  • The TTM is -61.877. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.341MRQ-5.671+0.331
MRQ-5.671TTM-61.877+56.206
TTM-61.877YOY-8.929-52.948
TTM-61.8775Y-7.702-54.176
5Y-7.70210Y-21.285+13.584
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.341-2.300-3.041
MRQ-5.671-2.656-3.015
TTM-61.877-2.718-59.159
YOY-8.929-4.145-4.784
5Y-7.702-6.258-1.444
10Y-21.285-6.315-14.970
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ocular Therapeutix Inc:

  • The EOD is -8.802. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.347. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.256. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.802MRQ-9.347+0.545
MRQ-9.347TTM-10.256+0.908
TTM-10.256YOY-9.847-0.409
TTM-10.2565Y-19.174+8.918
5Y-19.17410Y-31.797+12.623
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.802-2.974-5.828
MRQ-9.347-3.306-6.041
TTM-10.256-3.508-6.748
YOY-9.847-5.613-4.234
5Y-19.174-8.378-10.796
10Y-31.797-8.873-22.924
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ocular Therapeutix Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.27 means the investor is paying $7.27 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ocular Therapeutix Inc:

  • The EOD is 6.850. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.274. Based on the equity, the company is overpriced. -1
  • The TTM is 98.948. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD6.850MRQ7.274-0.424
MRQ7.274TTM98.948-91.674
TTM98.948YOY10.862+88.087
TTM98.9485Y21.647+77.301
5Y21.64710Y24.049-2.402
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.8501.914+4.936
MRQ7.2742.116+5.158
TTM98.9482.097+96.851
YOY10.8622.881+7.981
5Y21.6473.550+18.097
10Y24.0493.936+20.113
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ocular Therapeutix Inc.

3.1. Institutions holding Ocular Therapeutix Inc

Institutions are holding 50.112% of the shares of Ocular Therapeutix Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Deep Track Capital, LP6.21071.3749923076992307690
2023-12-31SUMMER ROAD LLC5.15421007660550153846125.1297
2023-12-31Opaleye Management Inc4.0847.19886070000-398000-6.1534
2023-12-31BlackRock Inc3.87650.000757615334179807.8221
2023-12-31Vanguard Group Inc3.44360.00055118102105712326.0312
2023-12-31Franklin Resources Inc3.02780.0094450015945001590
2023-12-31Logos Global Management LP2.69131.6653400000040000000
2023-12-31Deltec Asset Management LLC1.64412.4525244360738181018.5183
2023-12-31Geode Capital Management, LLC1.16860.000817368141072866.5839
2023-12-31State Street Corporation1.03590.00031539575-242290-13.5976
2023-12-31Longwood Capital Partners LLC0.88143.2888131000013100000
2023-09-30Citadel Advisors Llc0.86750.00091289356396053.169
2023-12-31Nuveen Asset Management, LLC0.68130.0015101254315050.1489
2023-12-31Sio Capital Management, LLC0.65360.98659714469714460
2023-12-31Millennium Management LLC0.52160.00157751678942713.0409
2023-12-31Great Point Partners LLC0.4710.53217000007000000
2023-12-31Cetera Investment Advisers0.45510.02456764006630010.8671
2023-12-31Northern Trust Corp0.45210.0005671984-1752-0.26
2023-12-31AXA SA0.42930.0092638126-1108-0.1733
2023-09-30D. E. Shaw & Co LP0.39350.0019584880-71225-10.8557
Total 38.1431117.550656691011+23697496+41.8%

3.2. Funds holding Ocular Therapeutix Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.2130.0021328916200
2024-03-28iShares Russell 2000 ETF1.89850.0392282164613620.0483
2024-02-29Franklin Biotechnology Discv A(acc)USD1.43041.1588212600000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.79860.01171186962-917-0.0772
2024-02-29Franklin Biotechnology Discovery A0.70481.0956104750000
2024-03-28iShares Russell 2000 Growth ETF0.6740.07821001729-1165-0.1162
2024-01-31Fidelity Small Cap Index0.54630.0159811936144081.8066
2024-01-31TIAA-CREF Quant Small-Cap Equity Instl0.52590.126878159000
2024-02-29UTM IM GBP AXA Framlington Biotech0.41171.093361195300
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.32520.0116483266157003.3578
2024-02-29Fidelity Extended Market Index0.30930.0121459758149373.358
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.27360.03840669313310048.6489
2024-02-29Vanguard Russell 2000 ETF0.19650.0308292061227848.4612
2024-03-28iShares Micro-Cap ETF0.17010.250225280818680.7444
2024-03-31BlackRock Extended Equity Market K0.15980.01482374336417037.0362
2023-12-31ERSTE STOCK BIOTEC EUR R01 A0.15870.38772357997698948.4787
2023-12-31NT R2000 Growth Index Fund - NL0.15510.027823053320410.8932
2023-12-31NT R2000 Index Fund - NL0.14880.013622110623331.0664
2024-03-31Russell 2000 Index Non-Lendable Fund E0.14810.03872201207356950.2003
2023-09-30BlackRock Extended Mkt Composite0.13520.004520090513660.6846
Total 11.38364.451416918960+422545+2.5%

3.3. Insider Transactions

Insiders are holding 3.681% of the shares of Ocular Therapeutix Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-26Summer Road LlcBUY9308517.52
2024-01-31Antony C MattessichSELL183384.95
2024-01-31Donald NotmanSELL64334.95
2024-01-31Philip C StrassburgerSELL68314.95
2024-01-31Rabia Gurses OzdenSELL77644.95
2023-08-30Antony C MattessichBUY65003.81
2023-07-07Rabia Gurses OzdenSELL8324.93

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Ocular Therapeutix Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5600.094+497%-0.089+116%0.019+2914%0.025+2112%
Book Value Per Share--0.6130.188+226%0.382+60%0.264+132%0.306+101%
Current Ratio--6.6554.351+53%5.633+18%6.248+7%7.934-16%
Debt To Asset Ratio--0.6380.872-27%0.666-4%0.803-20%0.642-1%
Debt To Equity Ratio--1.76618.096-90%2.158-18%6.441-73%3.443-49%
Dividend Per Share----0%-0%0.001-100%0.003-100%
Eps---0.197-0.136-31%-0.119-39%-0.135-31%-0.111-44%
Free Cash Flow Per Share---0.119-0.120+0%-0.107-11%-0.113-5%-0.091-24%
Free Cash Flow To Equity Per Share--0.5740.157+265%-0.104+118%0.046+1146%0.030+1797%
Gross Profit Margin--1.9065.949-68%1.776+7%2.080-8%1.605+19%
Intrinsic Value_10Y_max---4.718--------
Intrinsic Value_10Y_min---6.914--------
Intrinsic Value_1Y_max---0.379--------
Intrinsic Value_1Y_min---0.495--------
Intrinsic Value_3Y_max---1.210--------
Intrinsic Value_3Y_min---1.668--------
Intrinsic Value_5Y_max---2.127--------
Intrinsic Value_5Y_min---3.029--------
Market Cap624233433.600-6%662876455.680669936238.560-1%591907059.360+12%1029019089.888-36%1287685818.936-49%
Net Profit Margin---1.974-1.523-23%-1.265-36%-8.176+314%-25.024+1168%
Operating Margin---1.354-1.423+5%-1.538+14%-7.535+456%-24.213+1688%
Operating Ratio--2.3542.422-3%2.538-7%8.604-73%25.057-91%
Pb Ratio6.850-6%7.27498.948-93%10.862-33%21.647-66%24.049-70%
Pe Ratio-5.341+6%-5.671-61.877+991%-8.929+57%-7.702+36%-21.285+275%
Price Per Share4.200-6%4.4604.508-1%3.983+12%6.924-36%8.664-49%
Price To Free Cash Flow Ratio-8.802+6%-9.347-10.256+10%-9.847+5%-19.174+105%-31.797+240%
Price To Total Gains Ratio7.496-6%7.960-10.103+227%-50.595+736%27.010-71%-153.634+2030%
Quick Ratio--6.3664.116+55%5.430+17%6.012+6%9.283-31%
Return On Assets---0.116-0.143+23%-0.097-16%-0.153+32%-0.165+42%
Return On Equity---0.321-2.709+745%-0.318-1%-1.273+297%-0.762+138%
Total Gains Per Share--0.5600.094+497%-0.089+116%0.019+2820%0.028+1882%
Usd Book Value--91131000.00027945500.000+226%56801500.000+60%39310650.000+132%45425700.000+101%
Usd Book Value Change Per Share--0.5600.094+497%-0.089+116%0.019+2914%0.025+2112%
Usd Book Value Per Share--0.6130.188+226%0.382+60%0.264+132%0.306+101%
Usd Dividend Per Share----0%-0%0.001-100%0.003-100%
Usd Eps---0.197-0.136-31%-0.119-39%-0.135-31%-0.111-44%
Usd Free Cash Flow---17729000.000-17784250.000+0%-15829500.000-11%-16770500.000-5%-13461200.000-24%
Usd Free Cash Flow Per Share---0.119-0.120+0%-0.107-11%-0.113-5%-0.091-24%
Usd Free Cash Flow To Equity Per Share--0.5740.157+265%-0.104+118%0.046+1146%0.030+1797%
Usd Market Cap624233433.600-6%662876455.680669936238.560-1%591907059.360+12%1029019089.888-36%1287685818.936-49%
Usd Price Per Share4.200-6%4.4604.508-1%3.983+12%6.924-36%8.664-49%
Usd Profit---29220000.000-21704000.000-26%-15855500.000-46%-20023950.000-31%-15923550.000-46%
Usd Revenue--14802000.00014578000.000+2%12873500.000+15%8747850.000+69%4581975.000+223%
Usd Total Gains Per Share--0.5600.094+497%-0.089+116%0.019+2820%0.028+1882%
 EOD+2 -6MRQTTM+24 -10YOY+22 -125Y+21 -1510Y+21 -15

4.2. Fundamental Score

Let's check the fundamental score of Ocular Therapeutix Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.341
Price to Book Ratio (EOD)Between0-16.850
Net Profit Margin (MRQ)Greater than0-1.974
Operating Margin (MRQ)Greater than0-1.354
Quick Ratio (MRQ)Greater than16.366
Current Ratio (MRQ)Greater than16.655
Debt to Asset Ratio (MRQ)Less than10.638
Debt to Equity Ratio (MRQ)Less than11.766
Return on Equity (MRQ)Greater than0.15-0.321
Return on Assets (MRQ)Greater than0.05-0.116
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Ocular Therapeutix Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5015.225
Ma 20Greater thanMa 507.257
Ma 50Greater thanMa 1008.562
Ma 100Greater thanMa 2006.459
OpenGreater thanClose4.440
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  1,76401,76401,76401,764-1,7640



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets252,060
Total Liabilities160,929
Total Stockholder Equity91,131
 As reported
Total Liabilities 160,929
Total Stockholder Equity+ 91,131
Total Assets = 252,060

Assets

Total Assets252,060
Total Current Assets232,235
Long-term Assets19,825
Total Current Assets
Cash And Cash Equivalents 195,957
Net Receivables 26,179
Inventory 2,305
Other Current Assets 7,794
Total Current Assets  (as reported)232,235
Total Current Assets  (calculated)232,235
+/-0
Long-term Assets
Property Plant Equipment 18,211
Other Assets 0
Long-term Assets  (as reported)19,825
Long-term Assets  (calculated)18,211
+/- 1,614

Liabilities & Shareholders' Equity

Total Current Liabilities34,896
Long-term Liabilities126,033
Total Stockholder Equity91,131
Total Current Liabilities
Short-term Debt 1,586
Accounts payable 4,389
Other Current Liabilities 28,666
Total Current Liabilities  (as reported)34,896
Total Current Liabilities  (calculated)34,641
+/- 255
Long-term Liabilities
Long term Debt 74,925
Capital Lease Obligations 8,464
Long-term Liabilities Other 108
Long-term Liabilities  (as reported)126,033
Long-term Liabilities  (calculated)83,497
+/- 42,536
Total Stockholder Equity
Common Stock12
Retained Earnings -697,578
Other Stockholders Equity 788,697
Total Stockholder Equity (as reported)91,131
Total Stockholder Equity (calculated)91,131
+/-0
Other
Capital Stock12
Cash and Short Term Investments 195,957
Common Stock Shares Outstanding 84,430
Current Deferred Revenue255
Liabilities and Stockholders Equity 252,060
Net Debt -112,568
Net Invested Capital 166,056
Net Working Capital 197,339
Property Plant and Equipment Gross 38,471
Short Long Term Debt Total 83,389



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
25,285
0
0
0
19,146
15,080
23,974
83,878
78,193
71,497
129,470
119,319
110,306
100,432
89,901
82,347
74,939
90,697
79,675
64,399
55,431
76,685
70,459
70,270
73,043
101,490
89,742
88,710
78,740
72,857
107,260
98,219
261,863
243,040
230,707
217,739
204,887
187,622
173,071
158,579
149,289
128,573
122,558
162,384
252,060
252,060162,384122,558128,573149,289158,579173,071187,622204,887217,739230,707243,040261,86398,219107,26072,85778,74088,71089,742101,49073,04370,27070,45976,68555,43164,39979,67590,69774,93982,34789,901100,432110,306119,319129,47071,49778,19383,87823,97415,08019,14600025,285
   > Total Current Assets 
0
0
0
0
18,014
13,811
22,594
82,274
76,183
69,470
126,639
115,898
106,983
97,097
84,974
76,824
69,898
83,276
68,328
52,453
43,339
64,476
58,472
58,274
56,193
79,172
65,436
69,636
60,170
55,153
90,293
81,903
246,160
228,132
216,523
203,932
191,300
174,652
160,322
145,615
129,627
107,162
100,712
141,258
232,235
232,235141,258100,712107,162129,627145,615160,322174,652191,300203,932216,523228,132246,16081,90390,29355,15360,17069,63665,43679,17256,19358,27458,47264,47643,33952,45368,32883,27669,89876,82484,97497,097106,983115,898126,63969,47076,18382,27422,59413,81118,0140000
       Cash And Cash Equivalents 
23,854
0
0
0
17,505
12,750
19,944
80,892
37,393
12,523
78,686
41,198
30,784
46,212
48,170
52,234
32,936
54,682
63,049
51,165
41,538
62,911
56,834
56,861
54,062
76,251
61,765
65,414
54,437
48,152
84,294
70,642
228,057
209,378
191,860
179,281
164,164
145,417
134,539
120,950
102,300
79,026
66,606
110,550
195,957
195,957110,55066,60679,026102,300120,950134,539145,417164,164179,281191,860209,378228,05770,64284,29448,15254,43765,41461,76576,25154,06256,86156,83462,91141,53851,16563,04954,68232,93652,23448,17046,21230,78441,19878,68612,52337,39380,89219,94412,75017,50500023,854
       Short-term Investments 
60
0
0
0
60
60
60
60
37,435
54,900
45,036
72,445
74,280
49,244
35,717
23,513
35,209
25,697
3,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000003,00025,69735,20923,51335,71749,24474,28072,44545,03654,90037,4356060606000060
       Net Receivables 
0
0
0
0
269
306
61
54
329
352
164
189
193
227
223
243
250
244
211
278
226
170
285
240
201
276
615
1,114
2,548
3,429
2,874
7,779
12,252
13,631
18,734
19,552
21,135
23,207
20,482
19,802
21,325
21,124
27,309
23,589
26,179
26,17923,58927,30921,12421,32519,80220,48223,20721,13519,55218,73413,63112,2527,7792,8743,4292,5481,11461527620124028517022627821124425024322322719318916435232954613062690000
       Inventory 
0
0
0
0
0
87
109
117
133
158
145
147
134
127
149
126
113
96
90
127
122
139
131
102
217
265
762
895
954
1,107
1,067
1,154
1,201
1,123
1,112
1,222
1,250
1,358
1,500
1,545
1,974
2,266
2,204
2,257
2,305
2,3052,2572,2042,2661,9741,5451,5001,3581,2501,2221,1121,1231,2011,1541,0671,10795489576226521710213113912212790961131261491271341471451581331171098700000
   > Long-term Assets 
0
0
0
0
1,132
1,269
1,380
1,604
2,010
2,027
2,831
3,421
3,323
3,335
4,927
5,523
5,041
7,421
11,347
11,946
12,092
12,209
11,987
11,996
16,850
22,318
24,306
19,074
18,570
17,704
16,967
16,316
15,703
14,908
14,184
13,807
13,587
12,970
12,749
12,964
19,662
21,411
21,846
21,126
19,825
19,82521,12621,84621,41119,66212,96412,74912,97013,58713,80714,18414,90815,70316,31616,96717,70418,57019,07424,30622,31816,85011,99611,98712,20912,09211,94611,3477,4215,0415,5234,9273,3353,3233,4212,8312,0272,0101,6041,3801,2691,1320000
       Property Plant Equipment 
785
0
0
0
904
1,041
1,152
1,376
1,782
1,799
2,603
3,193
3,095
3,107
3,199
3,795
3,313
5,693
9,619
10,218
10,478
10,595
10,373
10,382
10,236
15,704
17,542
17,310
16,806
15,940
15,203
14,552
13,939
13,144
12,420
12,043
11,823
11,206
10,985
11,200
17,898
19,647
20,082
19,362
18,211
18,21119,36220,08219,64717,89811,20010,98511,20611,82312,04312,42013,14413,93914,55215,20315,94016,80617,31017,54215,70410,23610,38210,37310,59510,47810,2189,6195,6933,3133,7953,1993,1073,0953,1932,6031,7991,7821,3761,1521,041904000785
       Long-term Assets Other 
0
0
0
0
228
228
228
228
228
228
228
228
228
228
1,728
1,728
1,728
1,728
1,728
1,728
1,614
1,614
1,614
1,614
6,614
6,614
6,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
0
01,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7641,7646,7646,6146,6141,6141,6141,6141,6141,7281,7281,7281,7281,7281,7282282282282282282282282282282280000
> Total Liabilities 
6,073
0
0
0
78,618
3,933
93,409
18,276
19,497
19,424
20,358
20,511
20,718
20,262
19,453
20,053
22,931
26,792
31,650
28,477
29,284
27,501
24,730
24,753
37,168
75,842
81,484
77,409
82,370
83,516
101,916
102,345
185,768
159,632
150,460
130,399
116,888
107,827
107,268
112,350
113,910
118,862
119,471
154,531
160,929
160,929154,531119,471118,862113,910112,350107,268107,827116,888130,399150,460159,632185,768102,345101,91683,51682,37077,40981,48475,84237,16824,75324,73027,50129,28428,47731,65026,79222,93120,05319,45320,26220,71820,51120,35819,42419,49718,27693,4093,93378,6180006,073
   > Total Current Liabilities 
3,475
0
0
0
3,342
2,069
4,489
3,379
5,874
7,227
9,591
11,181
5,378
6,003
6,419
8,243
8,300
8,656
13,130
10,945
13,426
13,151
11,899
13,406
9,159
8,614
10,127
11,005
12,029
11,112
13,803
22,906
26,664
27,437
21,550
25,158
26,337
23,960
26,113
29,269
31,395
29,715
32,357
35,066
34,896
34,89635,06632,35729,71531,39529,26926,11323,96026,33725,15821,55027,43726,66422,90613,80311,11212,02911,00510,1278,6149,15913,40611,89913,15113,42610,94513,1308,6568,3008,2436,4196,0035,37811,1819,5917,2275,8743,3794,4892,0693,3420003,475
       Short-term Debt 
0
0
0
0
1,806
152
1,085
0
1,354
2,860
4,370
5,883
15,272
1,161
2,466
3,772
1,549
897
2,444
3,993
5,545
6,071
6,082
6,094
0
675
1,024
1,073
1,126
3,255
5,384
7,503
9,648
9,711
1,487
1,554
1,624
1,696
1,771
1,744
1,599
1,818
3,796
1,878
1,586
1,5861,8783,7961,8181,5991,7441,7711,6961,6241,5541,4879,7119,6487,5035,3843,2551,1261,0731,02467506,0946,0826,0715,5453,9932,4448971,5493,7722,4661,16115,2725,8834,3702,8601,35401,0851521,8060000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
1,354
0
0
0
15,272
0
2,466
3,772
1,549
897
17,818
3,993
5,545
6,071
6,082
6,094
0
675
0
0
0
2,074
4,146
6,206
8,290
8,290
0
0
0
0
0
0
0
0
2,083
0
0
002,083000000008,2908,2906,2064,1462,07400067506,0946,0826,0715,5453,99317,8188971,5493,7722,466015,2720001,35400000000
       Accounts payable 
583
0
0
0
545
996
1,525
649
1,316
2,195
2,812
1,624
1,957
2,063
1,611
1,680
2,116
3,754
6,307
2,599
3,571
3,477
2,137
2,777
2,965
3,902
4,044
3,461
3,268
2,839
2,650
3,238
2,709
4,152
3,881
4,246
4,592
3,420
3,703
5,308
5,123
5,441
3,572
3,984
4,389
4,3893,9843,5725,4415,1235,3083,7033,4204,5924,2463,8814,1522,7093,2382,6502,8393,2683,4614,0443,9022,9652,7772,1373,4773,5712,5996,3073,7542,1161,6801,6112,0631,9571,6242,8122,1951,3166491,525996545000583
       Other Current Liabilities 
1,086
0
0
0
741
671
1,629
2,480
3,016
1,922
2,284
3,591
3,379
2,779
2,342
2,791
4,635
4,005
4,379
4,353
4,310
3,603
3,680
4,535
6,194
675
5,059
6,471
7,635
5,018
5,769
12,165
2,307
1,574
4,182
7,358
7,121
17,636
19,450
21,614
24,097
21,993
24,598
28,887
28,666
28,66628,88724,59821,99324,09721,61419,45017,6367,1217,3584,1821,5742,30712,1655,7695,0187,6356,4715,0596756,1944,5353,6803,6034,3104,3534,3794,0054,6352,7912,3422,7793,3793,5912,2841,9223,0162,4801,6296717410001,086
   > Long-term Liabilities 
0
0
0
0
75,276
1,864
88,920
14,897
13,623
12,197
10,767
9,330
15,340
14,259
13,034
11,810
14,631
18,136
18,520
17,532
15,858
14,350
12,831
11,347
28,009
67,228
71,357
66,404
70,341
72,404
88,113
79,439
159,104
132,195
128,910
105,241
90,551
83,867
81,155
83,081
82,515
89,147
87,114
119,465
126,033
126,033119,46587,11489,14782,51583,08181,15583,86790,551105,241128,910132,195159,10479,43988,11372,40470,34166,40471,35767,22828,00911,34712,83114,35015,85817,53218,52018,13614,63111,81013,03414,25915,3409,33010,76712,19713,62314,89788,9201,86475,2760000
       Long term Debt Total 
0
0
0
0
0
0
13,594
14,776
13,511
12,094
10,673
9,249
15,272
14,204
12,992
11,778
14,094
16,821
15,374
13,924
12,471
11,014
9,548
8,073
24,788
47,857
48,796
48,098
49,312
48,286
47,322
42,766
41,243
39,729
50,239
50,822
51,435
52,058
52,695
53,344
54,006
54,679
53,284
0
0
0053,28454,67954,00653,34452,69552,05851,43550,82250,23939,72941,24342,76647,32248,28649,31248,09848,79647,85724,7888,0739,54811,01412,47113,92415,37416,82114,09411,77812,99214,20415,2729,24910,67312,09413,51114,77613,594000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-1,806
-152
-1,085
0
-1,354
-2,860
-4,370
-5,883
-15,272
-1,161
-2,466
-3,772
-1,549
-897
-2,444
-3,993
-5,545
-6,071
-6,082
-6,094
0
7,909
9,493
9,206
8,905
6,516
4,110
1,703
-742
-1,121
6,770
6,355
5,924
5,472
4,999
4,610
8,678
8,114
5,606
7,251
6,878
6,8787,2515,6068,1148,6784,6104,9995,4725,9246,3556,770-1,121-7421,7034,1106,5168,9059,2069,4937,9090-6,094-6,082-6,071-5,545-3,993-2,444-897-1,549-3,772-2,466-1,161-15,272-5,883-4,370-2,860-1,3540-1,085-152-1,8060000
       Warrants
0
0
0
0
0
0
74,355
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000074,355000000
       Long-term Liabilities Other 
0
0
0
0
0
0
852
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,909
9,493
9,206
8,905
8,590
8,256
7,909
19,548
19,169
18,770
18,355
18,924
18,575
17,999
18,143
22,158
21,554
104
106
108
10810610421,55422,15818,14317,99918,57518,92418,35518,77019,16919,5487,9098,2568,5908,9059,2069,4937,909000000000000000000852000000
       Deferred Long Term Liability 
0
0
0
0
0
0
119
121
112
103
94
81
68
55
42
32
537
1,315
3,146
3,608
3,387
3,336
3,283
3,274
3,221
11,462
13,068
9,100
12,124
15,528
32,535
28,764
98,313
73,297
59,901
36,064
20,192
13,234
10,461
11,594
6,351
12,914
11,783
0
0
0011,78312,9146,35111,59410,46113,23420,19236,06459,90173,29798,31328,76432,53515,52812,1249,10013,06811,4623,2213,2743,2833,3363,3873,6083,1461,315537324255688194103112121119000000
> Total Stockholder Equity
19,212
0
0
0
-59,472
11,147
-69,435
65,602
58,696
52,073
109,112
98,808
89,588
80,170
70,448
62,294
52,008
63,905
48,025
35,922
26,147
49,184
45,729
45,517
35,875
25,648
8,258
11,301
-3,630
-10,659
5,344
-4,126
76,095
83,408
80,247
87,340
87,999
79,795
65,803
46,229
35,379
9,711
3,087
7,853
91,131
91,1317,8533,0879,71135,37946,22965,80379,79587,99987,34080,24783,40876,095-4,1265,344-10,659-3,63011,3018,25825,64835,87545,51745,72949,18426,14735,92248,02563,90552,00862,29470,44880,17089,58898,808109,11252,07358,69665,602-69,43511,147-59,47200019,212
   Common Stock
0
0
0
0
-74,344
2
0
2
2
2
2
2
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
5
5
5
6
6
8
8
8
8
8
8
8
8
8
8
8
8
12
12888888888888665554444443333322222222202-74,3440000
   Retained Earnings Total Equity00-667,842-647,160-616,842-601,300-577,112-558,346-545,804-541,954-544,611-536,130-539,251-453,639-441,695-405,127-383,615-357,598-338,820-314,367-297,243-279,844-264,834-251,030-237,265-224,163-208,596-189,902-173,879-161,057-151,461-140,016-129,176-118,539-107,015-97,006-89,428-81,474-74,180000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-1,675
-1,768
0
-83,878
-2,221
-2,221
-8
-16
-68
-2,939
10
5
-5
-9
0
-4,836
-5,341
-5,341
0
0
-7,627
-7,627
0
0
-10,019
-10,019
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000-10,019-10,01900-7,627-7,62700-5,341-5,341-4,8360-9-5510-2,939-68-16-8-2,221-2,221-83,8780-1,768-1,6750000
   Capital Surplus 
0
0
0
0
0
0
4,745
147,074
148,122
149,077
216,133
217,361
218,830
220,184
221,897
223,344
225,889
253,813
256,618
260,082
263,409
300,210
310,559
325,357
333,114
340,011
347,074
368,894
379,980
394,463
447,033
449,507
615,338
619,530
624,850
629,286
633,795
638,133
642,907
647,521
652,213
656,863
670,921
0
0
00670,921656,863652,213647,521642,907638,133633,795629,286624,850619,530615,338449,507447,033394,463379,980368,894347,074340,011333,114325,357310,559300,210263,409260,082256,618253,813225,889223,344221,897220,184218,830217,361216,133149,077148,122147,0744,745000000
   Treasury Stock000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
2,983
80,701
-69,610
147,074
150,343
149,077
216,133
217,361
218,830
220,184
221,897
223,344
225,889
253,813
256,618
264,918
263,409
300,210
310,559
325,357
340,741
340,011
347,074
368,894
389,999
394,463
447,033
449,507
615,338
619,530
624,850
629,286
633,795
638,133
642,907
647,521
652,213
656,863
670,921
676,203
788,697
788,697676,203670,921656,863652,213647,521642,907638,133633,795629,286624,850619,530615,338449,507447,033394,463389,999368,894347,074340,011340,741325,357310,559300,210263,409264,918256,618253,813225,889223,344221,897220,184218,830217,361216,133149,077150,343147,074-69,61080,7012,9830000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue58,443
Cost of Revenue-5,281
Gross Profit53,16253,162
 
Operating Income (+$)
Gross Profit53,162
Operating Expense-135,544
Operating Income-82,382-82,382
 
Operating Expense (+$)
Research Development61,055
Selling General Administrative69,661
Selling And Marketing Expenses4,828
Operating Expense135,544135,544
 
Net Interest Income (+$)
Interest Income2,947
Interest Expense-11,338
Other Finance Cost-2,304
Net Interest Income-6,087
 
Pretax Income (+$)
Operating Income-82,382
Net Interest Income-6,087
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-80,736-84,028
EBIT - interestExpense = -93,720
-80,736
-69,398
Interest Expense11,338
Earnings Before Interest and Taxes (EBIT)-82,382-69,398
Earnings Before Interest and Taxes (EBITDA)-79,399
 
After tax Income (+$)
Income Before Tax-80,736
Tax Provision-0
Net Income From Continuing Ops-67,058-80,736
Net Income-80,736
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses140,825
Total Other Income/Expenses Net1,6466,087
 

Technical Analysis of Ocular Therapeutix Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ocular Therapeutix Inc. The general trend of Ocular Therapeutix Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ocular Therapeutix Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ocular Therapeutix Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 8.83 < 10.28 < 11.31.

The bearish price targets are: 3.97 > 3.7599 > 3.46.

Tweet this
Ocular Therapeutix Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ocular Therapeutix Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ocular Therapeutix Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ocular Therapeutix Inc. The current macd is -1.08688187.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ocular Therapeutix Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Ocular Therapeutix Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Ocular Therapeutix Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Ocular Therapeutix Inc Daily Moving Average Convergence/Divergence (MACD) ChartOcular Therapeutix Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ocular Therapeutix Inc. The current adx is 34.99.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Ocular Therapeutix Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Ocular Therapeutix Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ocular Therapeutix Inc. The current sar is 6.273024.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Ocular Therapeutix Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ocular Therapeutix Inc. The current rsi is 15.23. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Ocular Therapeutix Inc Daily Relative Strength Index (RSI) ChartOcular Therapeutix Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ocular Therapeutix Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ocular Therapeutix Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ocular Therapeutix Inc Daily Stochastic Oscillator ChartOcular Therapeutix Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ocular Therapeutix Inc. The current cci is -156.31507829.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Ocular Therapeutix Inc Daily Commodity Channel Index (CCI) ChartOcular Therapeutix Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ocular Therapeutix Inc. The current cmo is -83.76161767.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ocular Therapeutix Inc Daily Chande Momentum Oscillator (CMO) ChartOcular Therapeutix Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ocular Therapeutix Inc. The current willr is -99.14893617.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Ocular Therapeutix Inc Daily Williams %R ChartOcular Therapeutix Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ocular Therapeutix Inc.

Ocular Therapeutix Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ocular Therapeutix Inc. The current atr is 0.58570543.

Ocular Therapeutix Inc Daily Average True Range (ATR) ChartOcular Therapeutix Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ocular Therapeutix Inc. The current obv is 16,758,406.

Ocular Therapeutix Inc Daily On-Balance Volume (OBV) ChartOcular Therapeutix Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ocular Therapeutix Inc. The current mfi is 6.94939563.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Ocular Therapeutix Inc Daily Money Flow Index (MFI) ChartOcular Therapeutix Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ocular Therapeutix Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Ocular Therapeutix Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ocular Therapeutix Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5015.225
Ma 20Greater thanMa 507.257
Ma 50Greater thanMa 1008.562
Ma 100Greater thanMa 2006.459
OpenGreater thanClose4.440
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ocular Therapeutix Inc with someone you think should read this too:
  • Are you bullish or bearish on Ocular Therapeutix Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ocular Therapeutix Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ocular Therapeutix Inc

I send you an email if I find something interesting about Ocular Therapeutix Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Ocular Therapeutix Inc.

Receive notifications about Ocular Therapeutix Inc in your mailbox!